Skip to main content
Top
Published in: Annals of Surgical Oncology 10/2007

01-10-2007 | Gastrointestinal Oncology

Changing Patterns of Prognosticators During 15-Year Follow-Up of Advanced Gastric Cancer after Radical Gastrectomy and Adjuvant Chemotherapy: A 15-Year Follow-Up Study at a Single Korean Institute

Authors: Yong Wha Moon, MD, Hei-Cheul Jeung, MD, PhD, Sun Young Rha, MD, PhD, Nae Choon Yoo, MD, PhD, Jae Kyung Roh, MD, PhD, Sung Hoon Noh, MD, PhD, Byung Soo Kim, MD, PhD, Hyun Cheol Chung, MD, PhD

Published in: Annals of Surgical Oncology | Issue 10/2007

Login to get access

Abstract

Background

We evaluated the long-term natural history of gastric cancer after radical gastrectomy and adjuvant chemotherapy through a 15-year follow-up study at a single institute.

Methods

Five hundred patients with advanced gastric adenocarcinoma who received radical gastrectomy and adjuvant chemotherapy were included in this long-term follow-up study. Patients were evaluated by imaging studies and upper gastrointestinal series or endoscopy every 6 months until the 10th year after surgery. Since then, the patients have been followed yearly in the same manner.

Results

The median follow-up period was 190.5 months. The recurrence rate in 5-year survivors was 10.8%. The dominant recurrence pattern was peritoneal carcinomatosis within 5 years and distant metastasis after 5 years post gastrectomy. Tumor stage was a clear-cut prognosticator within 5 years post gastrectomy, but was no longer informative in 5–10 years. At this period, only stage IV (IB–IIIB vs IVM0) was a significantly poor prognosticator. After 10 years, second primary cancer (seven cases) became as important an issue as recurrence of primary gastric cancer (six cases).

Conclusions

In patients with gastric carcinoma treated with radical gastrectomy and adjuvant chemotherapy, late recurrence after 5 years post gastrectomy was not rare. Prognosticators were varied depending on the length of time after surgery. Tumor factors including stage were prognosticators within 5 years post gastrectomy, but tumor factors except stage IV had no prognostic value after 5 years. In the 5–10 years post gastrectomy, only stage IV (IB–IIIB vs IVM0) was a poor prognosticator. Also, after 10 years, there were no prognosticators.
Literature
1.
go back to reference Shin HR, Jung KW, Won YJ, Park JG. 139 KCCR-affiliated Hospitals. 2002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 Hospitals. Cancer Res Treat 2004; 36:103–14CrossRefPubMed Shin HR, Jung KW, Won YJ, Park JG. 139 KCCR-affiliated Hospitals. 2002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 Hospitals. Cancer Res Treat 2004; 36:103–14CrossRefPubMed
2.
go back to reference Desai AM, Pareek M, Nightingale PG, Fielding JW. Improving outcomes in gastric cancer over 20 years. Gastric Cancer 2004; 7:196–201PubMedCrossRef Desai AM, Pareek M, Nightingale PG, Fielding JW. Improving outcomes in gastric cancer over 20 years. Gastric Cancer 2004; 7:196–201PubMedCrossRef
3.
go back to reference Jeung HC, Rha SY, Noh SH, Min JS, Kim BS, Chung HC. Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. Cancer 2001; 91:2016–25PubMedCrossRef Jeung HC, Rha SY, Noh SH, Min JS, Kim BS, Chung HC. Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. Cancer 2001; 91:2016–25PubMedCrossRef
4.
go back to reference Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopathologic characteristics and prognostic factors in 10783 patients with gastric cancer. Gastric Cancer 1998; 1:125–33PubMedCrossRef Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopathologic characteristics and prognostic factors in 10783 patients with gastric cancer. Gastric Cancer 1998; 1:125–33PubMedCrossRef
5.
go back to reference Moriwaki Y, Kunisaki C, Kobayashi S, Harada H, Imai S, Kido Y, Kasaoka C. Progressive improvement of prognosis for patients with gastric cancer (dynamic stage grouping) with increasing survival interval from initial staging: how much longer can a given survivor expect to live? Surgery 2003; 133:135–40PubMedCrossRef Moriwaki Y, Kunisaki C, Kobayashi S, Harada H, Imai S, Kido Y, Kasaoka C. Progressive improvement of prognosis for patients with gastric cancer (dynamic stage grouping) with increasing survival interval from initial staging: how much longer can a given survivor expect to live? Surgery 2003; 133:135–40PubMedCrossRef
6.
go back to reference Greene FL, Balch CM, Page DL, et al. AJCC Cancer Staging Manual, 6th ed. (Springer-Verlag, New York, 2002) Greene FL, Balch CM, Page DL, et al. AJCC Cancer Staging Manual, 6th ed. (Springer-Verlag, New York, 2002)
7.
go back to reference Grau JJ, Martin M, Fuster J, et al. Impact of adjuvant chemotherapy in the long-term outcome of patients with resected gastric cancer. J Surg Oncol 2003; 82:234–40PubMedCrossRef Grau JJ, Martin M, Fuster J, et al. Impact of adjuvant chemotherapy in the long-term outcome of patients with resected gastric cancer. J Surg Oncol 2003; 82:234–40PubMedCrossRef
8.
go back to reference Maehara Y, Moriguchi S, Sakaguchi Y, et al. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol 1990; 45:169–72PubMedCrossRef Maehara Y, Moriguchi S, Sakaguchi Y, et al. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol 1990; 45:169–72PubMedCrossRef
9.
go back to reference Moertel CG, O’Connel M, Lavin PT. Chemotherapy of gastric cancer. 1979 AACR Annual Meeting Proceedings. 1979; 288:20 Moertel CG, O’Connel M, Lavin PT. Chemotherapy of gastric cancer. 1979 AACR Annual Meeting Proceedings. 1979; 288:20
10.
go back to reference Brugarolas A, Garcia-Moran M, Lacave AJ. Chemotherapy in advanced gastric cancer: a controlled clinical study. 1975 AACR Annual Meeting Proceedings. 1975; 169:16 Brugarolas A, Garcia-Moran M, Lacave AJ. Chemotherapy in advanced gastric cancer: a controlled clinical study. 1975 AACR Annual Meeting Proceedings. 1975; 169:16
11.
go back to reference Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87:236–42PubMedCrossRef Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87:236–42PubMedCrossRef
12.
go back to reference Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 2000; 87:353–7PubMedCrossRef Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 2000; 87:353–7PubMedCrossRef
14.
go back to reference Naumov GN, MacDonald IC, Weinmeister PM, et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 2002; 62:2162–8PubMed Naumov GN, MacDonald IC, Weinmeister PM, et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 2002; 62:2162–8PubMed
15.
go back to reference Maehara Y, Okuyama T, Oshiro T, Baba H, Adachi Y, Sugimachi K. Analysis of 390 patients surviving 10 years or longer after curative resection for gastric cancer. Oncology 1994; 51:366–71PubMedCrossRef Maehara Y, Okuyama T, Oshiro T, Baba H, Adachi Y, Sugimachi K. Analysis of 390 patients surviving 10 years or longer after curative resection for gastric cancer. Oncology 1994; 51:366–71PubMedCrossRef
16.
go back to reference Adachi Y, Mori M, Maehara Y, Sugimachi K. Long-term survival after resection for advanced gastric carcinoma. J Clin Gastroenterol 1995; 21:208–10PubMedCrossRef Adachi Y, Mori M, Maehara Y, Sugimachi K. Long-term survival after resection for advanced gastric carcinoma. J Clin Gastroenterol 1995; 21:208–10PubMedCrossRef
17.
go back to reference Schlag P, Schreml W, Gaus W, Herfarth C, Linder MM, Queisser W, Trede M. Adjuvant 5-fluorouracil and BCNU chemotherapy in gastric cancer: 3-year results. Recent Results Cancer Res 1982;80: 277–83PubMed Schlag P, Schreml W, Gaus W, Herfarth C, Linder MM, Queisser W, Trede M. Adjuvant 5-fluorouracil and BCNU chemotherapy in gastric cancer: 3-year results. Recent Results Cancer Res 1982;80: 277–83PubMed
18.
go back to reference Maehara Y, Emi Y, Baba H, Adachi Y, Akazawa K, Ichiyoshi Y, Sugimachi K. Recurrences and related characteristics of gastric cancer. Br J Cancer 1996; 74:975–9PubMed Maehara Y, Emi Y, Baba H, Adachi Y, Akazawa K, Ichiyoshi Y, Sugimachi K. Recurrences and related characteristics of gastric cancer. Br J Cancer 1996; 74:975–9PubMed
19.
go back to reference Chen CN, Lin JJ, Chen JJ, et al. Gene expression profile predicts patient survival of gastric cancer after surgical resection. J Clin Oncol 2005; 23:7286–95PubMedCrossRef Chen CN, Lin JJ, Chen JJ, et al. Gene expression profile predicts patient survival of gastric cancer after surgical resection. J Clin Oncol 2005; 23:7286–95PubMedCrossRef
20.
go back to reference Ikeda Y, Saku M, Kishihara F, Maehara Y. Effective follow-up for recurrence or a second primary cancer in patients with early gastric cancer. Br J Surg 2005; 92:235–9PubMedCrossRef Ikeda Y, Saku M, Kishihara F, Maehara Y. Effective follow-up for recurrence or a second primary cancer in patients with early gastric cancer. Br J Surg 2005; 92:235–9PubMedCrossRef
21.
go back to reference Ikeda Y, Saku M, Kawanaka H, Nonaka M, Yoshida K. Features of second primary cancer in patients with gastric cancer. Oncology 2003; 65:113–7PubMedCrossRef Ikeda Y, Saku M, Kawanaka H, Nonaka M, Yoshida K. Features of second primary cancer in patients with gastric cancer. Oncology 2003; 65:113–7PubMedCrossRef
Metadata
Title
Changing Patterns of Prognosticators During 15-Year Follow-Up of Advanced Gastric Cancer after Radical Gastrectomy and Adjuvant Chemotherapy: A 15-Year Follow-Up Study at a Single Korean Institute
Authors
Yong Wha Moon, MD
Hei-Cheul Jeung, MD, PhD
Sun Young Rha, MD, PhD
Nae Choon Yoo, MD, PhD
Jae Kyung Roh, MD, PhD
Sung Hoon Noh, MD, PhD
Byung Soo Kim, MD, PhD
Hyun Cheol Chung, MD, PhD
Publication date
01-10-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9479-4

Other articles of this Issue 10/2007

Annals of Surgical Oncology 10/2007 Go to the issue